First Brazilian consensus on the management of localized and locally advanced urothelial bladder cancer: a SBU-SBOC-SBRT-LACOG-GU panel review

ABSTRACT

Introduction: Urothelial carcinoma, especially localized bladder cancer, has a substantial prevalence in Brazil with 9,480 new cases each year and 3,903 deaths, therefore progress is required in its management in order to decrease its recurrence and progression, and improve survival. Material and Methods: Medical oncologists, radiation oncologists, and urologists from Brazil conducted a meeting to vote the best approaches available in this country in the diagnosis, staging, and treatment of localized and locally advanced urothelial bladder carcinoma. The panel drew up 73 questions and answers were chosen considering the feasibility according to the access to drugs and the procedures used in this country. Each answer reaching 75% of voters was considered a consensus. The results of this consensus were compared with evidence published in the medical literature and rated with a level of evidence and grade of recommendation using the Oxford classification. Results: Transurethral resection of bladder tumors confirms the diagnosis of and provides initial treatment for non-muscle-invasive bladder cancers. Repeated resection is necessary in selected cases and should not delay further treatment. The use of intravesical Bacillus Calmette-Guérin is performed according to risk stratification, showing a significant reduction in tumor recurrence and progression, and improved disease-specific survival in intermediate- and high-risk patients. Radical cystectomy should be considered for high-progression risk cases after Bacillus Calmette-Guérin treatment failure and for localized muscle-invasive bladder cancer. Conclusion:  Management of urothelial carcinoma often requires a multidisciplinary team with surgical and clinical approaches, based on the expertise of professionals and evidence from the literature.

RESUMO

Introdução: O carcinoma urotelial, principalmente o câncer localizado de bexiga, tem prevalência substancial no Brasil com 9.480 novos casos a cada ano e 3.903 óbitos, portanto, é necessário avançar no seu manejo para diminuir sua recorrência e progressão, e melhorar a sobrevida. Material e Métodos: Médicos oncologistas, oncologistas de radiação e urologistas do Brasil realizaram uma reunião para votar as melhores abordagens disponíveis no país no diagnóstico, estadiamento e tratamento do carcinoma de bexiga urotelial localizado e localmente avançado. O painel elaborou 73 perguntas e as respostas foram escolhidas considerando a viabilidade de acordo com o acesso aos medicamentos e os procedimentos utilizados no país. Cada resposta que atingiu 75% dos eleitores foi considerada um consenso. Os resultados desse consenso foram comparados com as evidências publicadas na literatura médica e avaliados com um nível de evidência e grau de recomendação usando a classificação de Oxford. Resultados: A ressecção transuretral de tumores de bexiga confirma o diagnóstico e fornece tratamento inicial para cânceres de bexiga não músculo-invasivo. A ressecção repetida é necessária em casos selecionados e não deve atrasar o posterior tratamento. O uso do Bacillus Calmette-Guérin intravesical é realizado de acordo com a estratificação de risco, mostrando redução significativa na recorrência e progressão tumoral e melhora na sobrevida específica da doença em pacientes de risco intermediário e alto. A cistectomia radical deve ser considerada para casos de alto risco de progressão após falha no tratamento com Bacillus Calmette-Guérin e para câncer de bexiga músculo-invasivo localizado. Conclusão: O manejo do carcinoma urotelial muitas vezes requer uma equipe multidisciplinar com abordagens cirúrgicas e clínicas, com base na experiência dos profissionais e evidências da literatura.

Keywords:

Urinary bladder neoplasms - Cystectomy - Consensus - Carcinoma - Transitional cell - Administration - Intravesical.

Descritores:

Neoplasias da bexiga urinária - Cistectomia - Consenso - Carcinoma de célula transicional - Administração intravesical.

AUTHORS' CONTRIBUTIONS

All authors participated in the conceptualization, review, and revision of this manuscript. In addition, all authors have read and approved the final version of this manuscript.

ABBREVIATIONS:

American Society of Anesthesiologists (ASA); Bacillus

Calmette-Guérin (BCG);

Bladder cancer (BCa);

Brazilian Society of Clinical Oncology (SBOC); Brazilian Society of Radiotherapy (SBRT); Brazilian Society of Urology (SBU);

Carcinoma in situ (CIS); Computed tomography (CT); Cutaneous ureterostomy (CU); Disease-free survival (DFS); Disease-specific survival (DSS);

Enhanced recovery after surgery (ERAS); Grade of recommendation (GR);

Intravesical chemotherapy (IVC); Intravesical therapy (IVT);

Latin American Cooperative Oncology Group (LACOG); Level of evidence (LE);

Magnetic resonance imaging (MRI); Muscle-invasive bladder cancer (MIBC);

Non-muscle-invasive bladder cancer (NMIBC); Overall survival (OS);

Radical Cystectomy (RC); Recurrence-free survival (RFS); Repeating TURBT (re-TURBT); Transurethral resection (TUR);

Transurethral resection of bladder tumor (TURBT); Tri-modality therapy (TMT);

Upper urinary tract (UUT); Urothelial carcinoma (UC); Urothelial bladder carcinoma (UBC); Urinary diversion (UD);

With white light cystoscopy (WLC).

Publikationsverlauf

Eingereicht: 26. März 2021

Angenommen: 28. Mai 2021

Artikel online veröffentlicht:
22. Juni 2021

• REFERENCES

• World Health Organization (WHO). Cancer today. GLOBOCAN 2018 [Internet] Geneva: WHO; 2018. access in 2019 May 10 Available from: http://gco.iarc.fr/today/home
• Santos MO.. Estimativa 2018: incidência de câncer no Brasil. Rev Bras Cancerol [Internet] 2018; cited 2019 May 10 61 (01) 119-120 Available from: https://rbc.inca.gov.br/revista/index.php/revista/article/view/115
• Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM. et al Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 2018; Dec 74 (06) 784-795
• Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB.. Ethnic differences in bladder cancer survival. Urology 2011; Sep 78 (03) 544-549
• Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI. et al Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011; Aug 29 (04) 457-463
• Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA.. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle- invasive bladder cancer. Eur Urol 2011; Jul 60 (04) 713-720
• Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E. et al Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int 2011; Aug 108 (04) 539-545
• Heidegger I, Borena W, Pichler R.. The role of human papilloma virus in urological malignancies. Anticancer Res 2015; May 35 (05) 2513-2519
• Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P. et al Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; Feb 63 (02) 234-241
• Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM. et al Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl 2010; Sep 92 (06) 519-524
• Woldu SL, Bagrodia A, Lotan Y.. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2017; Mar 119 (03) 371-380
• Kaufman DS, Shipley WU, Feldman AS.. Bladder cancer. Lancet 2009; Jul 374: 239-249
• Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C. et al Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol 2013; 37 (03) 219-225
• Philips B, Sackett D, Badenoch D, Straus S, Haynes B, Dawes M.. Oxford Centre for Evidence-based Medicine (CEBM) - levels of evidence (March 2009) [Internet]. Oxford: CEBM; 2009. access in 2019 May 10 Available from: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/
• Larré S, Catto JWF, Cookson MS, Messing EM, Shariat SF, Soloway MS. et al Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur Urol 2013; 63 (06) 1049-1058
• Kishi K, Hirota T, Matsumoto K, Kakizoe T, Murase T, Fujita J.. Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases. J Urol 1981; Jan 125 (01) 36-39
• Vickers AJ, Bennette C, Kibel AS, Black A, Izmirlian G, Stephenson AJ. et al Who should be included in a clinical trial of screening for bladder cancer? A decision analysis of data from the prostate, lung, colorectal and ovarian cancer screening trial. Cancer 2013; Jan 119 (01) 143-149
• Van Der Aa MS, Bangma EW, Van Rhijn CH, Zwarthoff BWG, Van Der Kwast ECTH. Cystoscopy revisited as the gold standard for detection of bladder cancer recurrences: diagnostic review bias in a prospective randomised trial. J Urol 2009; Apr 8 (04) 374
• Van Der Aa MN, Steyerberg EW, Sen EF, Zwarthoff EC, Kirkels WJ, Van Der Kwast TH. et al Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int 2008; May 101 (09) 1106-1110
• Xiong Y, Li J, Ma S, Ge J, Zhou L, Li D. et al A meta-analysis of narrow band imaging for the diagnosis and therapeutic outcome of non-muscle invasive bladder cancer. PLoS One 2017; Feb 12 (02) e0170819
• Schumacher MC, Holmäng S, Davidsson T, Friedrich B, Pedersen J, Wiklund NP.. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic acid under visible and fluorescent light: results of a prospective, randomised, multicentre study. Eur Urol 2010; Feb 57 (02) 293-299
• Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M.. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004; Jan 171 (01) 135-138
• Jichlinski P, Leisinger HJ.. Fluorescence cystoscopy in the management of bladder cancer: a help for the urologist!. Urol Int 2005; 74 (02) 97-101
• Tatsugami K, Kuroiwa K, Kamoto T, Nishiyama H, Watanabe J, Ishikawa S. et al Evaluation of narrow-band imaging as a complementary method for the detection of bladder cancer. J Endourol 2010; 24 (11) 1807-1811
• Filbeck T, Roessler W, Knuechel R, Straub M, Kiel HJ, Wieland WF.. Clinical results of the transurethreal resection and evaluation of superficial bladder carcinomas by means of fluorescence diagnosis after intravesical instillation of 5-aminolevulinic acid. J Endourol 1999; 13 (02) 117-121
• Liu JJ, Droller MJ, Liao JC.. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol 2012; Aug 188 (02) 361-368
• Cowan NC.. CT urography for hematuria. Nat Rev Urol 2012; Mar 9 (04) 218-226
• Kantachuvesiri P, Mohammed A, Parkinson RJ. A retrospective study on the investigation of upper tract transitional cell carcinoma - are we detecting enough cases?. Eur J Surg Oncol 2014; Nov 40 (11) S180
• Lang EK, Macchia RJ, Thomas R, Ruiz-Deya G, Watson RA, Richter F. et al Computerized tomography tailored for the assessment of microscopic hematuria. J Urol 2002; Feb 167 2 Pt 1 547-554
• Jinzaki M, Matsumoto K, Kikuchi E, Sato K, Horiguchi Y, Nishiwaki Y. et al Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol 2011; May 196 (05) 1102-1109
• Takahashi N, Glockner JF, Hartman RP, King BF, Leibovich BC, Stanley DW. et al Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol 2010; Apr 183 (04) 1330-1365
• Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M. et al European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013; Jun 63 (06) 1059-1071
• Tang DH, Chang SS.. Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol 2015; Dec 7 (06) 351-364
• Van Der Meijden A, Oosterlinck W, Brausi M, Kurth KH, Sylvester R, Balincourt C. Significance of bladder biopsies in Ta, T1 bladder tumors: a report from the EORTC Genito- Urinary Tract Cancer Cooperative Group. EORTC-GU Group Superficial Bladder Committee. Eur Urol 1999; Apr 35 (04) 267-271
• Hara T, Takahashi M, Gondo T, Nagao K, Ohmi C, Sakano S. et al Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: retrospective analysis of 173 Japanese cases. Int J Urol 2009; Mar 16 (03) 293-298
• Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J. et al Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol 2018; May 8 (05) 665-670
• Kumano M, Miyake H, Nakano Y, Fujisawa M.. Significance of random bladder biopsies in non-muscle invasive bladder cancer. Curr Urol 2013; 7: 57-61
• Dahm P, Gschwend JE.. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol 2003; Dec 44 (06) 672-681
• Aragon-Ching J, Henson D.. Differences in survival among non-urothelial bladder cancers: analyses of SEER 1988-2008. J Clin Oncol 2018; 36 (Suppl 6) S425
• Furuse H, Ozono S.. Transurethral resection of the bladder tumour (TURBT) for non-muscle invasive bladder cancer: basic skills. Int J Urol 2010; Aug 17 (08) 698-699
• Rolevich A, Minich A, Nabebina T, Polyakov S, Krasny S, Sukonko O.. Surgeon has a major impact on long-term recurrence risk in patients with non-muscle invasive bladder cancer. Cent European J Urol 2016; 69 (02) 170-177
• Brausi M, Collette L, Kurth K, Van Der Meijden AP, Oosterlinck W, Witjes JA. et al Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002; 41 (05) 523-531
• Mariappan P, Zachou A, Grigor KM. Edinburgh Uro-Oncology Group. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010; 57: 843-849
• Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V. et al The impact of re- transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille CalmetteGuérin. BJU Int 2016; Jul 118 (01) 44-52
• Donat SM, Wei DC, McGuire MS, Herr HW.. The efficacy of transurethral biopsy for predicting the long-term clinical impact of prostatic invasive bladder cancer. J Urol 2001; May 165 (05) 1580-1584
• Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A. et al Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer. World J Urol 2019; Dec 37 (12) 2683-2689
• Nixon RG, Chang SS, Lafleur BJ, Smith JA, Cookson MS.. Carcinoma in situ and tumor multifocality predict the risk of prostatic urethral involvement at radical cystectomy in men with transitional cell carcinoma of the bladder. J Urol 2002; 167: 502-505
• Mungan MU, Canda AE, Tuzel E, Yorukoglu K, Kirkali Z.. Risk factors for mucosal prostatic urethral involvement in superficial transitional cell carcinoma of the bladder. Eur Urol 2005; Nov 48 (05) 760-763
• Luo S, Lin Y, Zhang W.. Does simultaneous transurethral resection of bladder tumor and prostate affect the recurrence of bladder tumor? A meta-analysis. J Endourol 2011; Feb 25 (02) 291-296
• Tsivian A, Shtricker A, Sidi AA.. Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver?. J Urol 2003; 170 6 Pt 1 2241-2243
• Shim JS, Choi H, Noh TI, Tae JH, Yoon SG, Kang SH. et al The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: results of a prospective study. Korean J Urol 2015; May 56 (06) 429-434
• Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F.. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010; Aug 58 (02) 185-190
• Sha N, Xie L, Chen T, Xing C, Liu X, Zhang Y. et al Impact of lymphovascular invasion on recurrence and progression rates in patients with pT1 urothelial carcinoma of bladder after transurethral resection. Onco Targets Ther 2015; 8: 3401-3406
• Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O'Donnell MA. et al The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int 2009; Feb 103 (04) 475-479
• Zare R, Grabe M, Hermann GG, Malmström PU.. Can routine outpatient follow-up of patients with bladder cancer be improved? A multicenter prospective observational assessment of blue light flexible cystoscopy and fulguration. Res Rep Urol 2018; Oct 10: 151-157
• Guerra ÁR, Aparicio TF, Bayonas IB, Martínez AP, Guillermo VM, Peralta DJ. et al Outpatient Holmium laser fulguration: a safe procedure for treatment of recurrence of non-muscle invasive bladder cancer. Actas Urol Esp 2018; Jun 42 (05) 309-315
• Al-Awamlh BAH, Lee R, Chughtai B, Donat SM, Sandhu JS, Herr HW. A cost- effectiveness analysis of management of low-risk non-muscle-invasive bladder cancer using office-based fulguration. Urology 2015; Feb 85 (02) 381-386
• Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M. et al A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011; 186 (06) 2158-2167
• Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S. et al Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?. Eur Urol 2016; Feb 69 (02) 231-244
• Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA.. Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 2013; Apr 11 (04) 477-484
• Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS.. Immediate post- transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality- of-evidence review. Eur Urol 2013; 64: 421-430
• Bosschieter J, Nieuwenhuijzen JA, Van Ginkel T, Vis AN, Witte B, Newling D. et al Value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol 2018; Feb 73 (02) 226-232
• Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood Junior DP. et al Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non-muscle-invasive bladder cancer on tumor recurrence: SWOG S0337 randomized clinical trial. JAMA 2018; 319: 1880-1888
• Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L. et al Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance. J Clin Oncol 2010; Feb 28 (04) 543-548
• Shang PF, Kwong J, Wang ZP, Tian J, Jiang L, Yang K. et al Intravesical Bacillus CalmetteGuérin versus epirubicin for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2011; May (05) CD006885
• Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E. et al An individual patient data meta-analysis of the long-term outcome of randomized studies comparing intravesical mitomycin C versus bacillus CalmetteGuérin for non-muscle-invasive bladder cancer. Eur Urol 2009; Aug 56 (02) 247-256
• Han RF, Pan JG.. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology 2006; Jun 67 (06) 1216-1223
• Sylvester RJ, Van Der MA, Lamm DL.. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; Nov 168 (05) 1964-1970
• Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K. et al A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; aug 88 (03) 209-216
• Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M.. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000; 2000 (04) CD001986
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA. et al Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; Apr 163 (04) 1124-1129
• Chen S, Zhang N, Shao J, Wang X.. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials. Int J Surg 2018; Apr 52: 248-257
• Bohle A, Jocham D, Bock PR.. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; Jan 169 (01) 90-95
• Järvinen R, Kaasinen E, Sankila A, Rintala E. FinnBladder Group. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomized Finn Bladder I study with a 20-year follow-up. Eur Urol 2009; Aug 56 (02) 260-265
• Shelley MD, Wilt TJ, Court J, Coles B, Kynaston H, Mason MD.. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004; Mar 93 (04) 485-490
• Böhle A, Bock PR.. Intravesical bacille CalmetteGuérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004; Apr 63 (04) 682-687
• Oddens J, Brausi M, Sylvester R, Bono A, Van de Beek C, Van Andel G. et al Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013; Mar 63 (03) 462-472
• Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Silva FC, Powell PH. et al Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; May 57 (05) 766-773
• Leliveld AM, Bastiaannet E, Doornweerd BHJ, Schaapveld MI, Jong IJ.. High-risk bladder cancer: current management and survival. Int Braz J Urol 2011; Mar/Apr 37 (02) 203-212
• D'Andrea D, Gontero P, Machado A, Waksman R, Shariat S, Chade D.. Comparative effectiveness of intravesical BCG-TICE and BCG-Moreau in patients with non-muscle invasive bladder cancer. Clin Genitourin Cancer 2020; Feb 18 (01) 20-25.e2
• Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG. et al Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; Oct 174 4 Pt 1 1242-1247
• Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C. et al Long- term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27mg in superficial bladder cancer. BJU Int 2002; May 89 (07) 671-680
• Lammers RJ, Witjes JA, Inman BA, Leibovitch I, Laufer M, Nativ O. et al The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. Eur Urol 2011; Jul 60 (01) 81-93
• Bendary L, Khalil S, Shahin A, Nawar N.. Intravesical gemcitabine versus bacillus calmette-guerin (BCG) in treatment of non-muscle invasive bladder cancer: short-term comparative study. J Urol 2011; Apr 185 (04) e664-e5
• Porena M, Del Zingaro M, Lazzeri M, Mearini L, Giannantoni A, Bini V. et al Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in highrisk superficial bladder cancer: a randomised prospective study. Urol Int 2010; 84 (01) 23-27
• Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S. A. randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2004; Jan 171 (01) 153-157
• Conrad S, Friedrich M, Schwaibold HP, , U Schildt KW, Huland H. Long term prophylaxis with Mitomycin C (MMC) further reduces tumor recurrence compared to short term prophylaxis with MMC or Bacillus Calmette-Guerin (BCG). J Urol 2004; Apr 171 (04) 71
• Bouffioux C, Kurth KH, Bono A, Oosterlinck W, Kruger CB, Pauw M. et al Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1995; Mar 153 3 Pt 2 934-941
• Tabayoyong WB, Kamat AM, O'Donnell MA, McKiernan JM, Ray-Zack MD, Palou J. et al Systematic review on the utilization of maintenance intravesical chemotherapy in the management of non-muscle-invasive bladder cancer. Eur Urol Focus 2018; Jul 4 (04) 512-521
• Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H. et al A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 1998; 33: 285-288
• Huland H, Kloppel G, Feddersen I, Otto U, Brachmann W, Hubmann H. et al Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 1990; Jul 144 (01) 68-71
• Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T. et al A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996; Aug 156 2 Pt 1 372-376
• Palou J, Rodríguez-Rubio F, Millán F, Algaba F, Rodríguez-Faba O, Huguet J. et al Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors. Urology 2009; Jun 73 (06) 1313-1317
• May M, Brookman-Amissah S, Roigas J, Hartmann A, Störkel S, Kristiansen G. et al Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organization classifications. Eur Urol 2009; Mar 57 (05) 850-858
• Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R. et al ICUD- EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol 2013; Jan 63 (01) 16-35
• Smith H, Weaver D, Barjenbruch O, Weinstein S, Ross Junior G.. Routine excretory urography in follow-up of superficial transitional cell carcinoma of bladder. Urology 1989; Oct 34 (04) 193-196
• Van Rhijn BW, Van Der Poel HG, Van Der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005; Jun 47 (06) 736-748
• Alhunaidi O, Zlotta AR.. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancer Med Sci 2019; 13: 905
• Solsona E, Iborra I, Dumont R, Rubio-Briones J, Casanova J, Almenar S.. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000; Sep 164 3 Pt 1 685-689
• Van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO.. Risk factors in carcinoma in situ of the urinary bladder. Urology 1995; 45: 581-586
• O'Donnell MA, Boehle A.. Treatment options for BCG failures. World J Urol 2006; Nov 24 (05) 481-487
• Herr HW, Dalbagni G.. Defining bacillus Calmette-Guerin refractory superficial bladder tumors. J Urol 2003; May 169 (05) 1706-1708
• Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M.. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008; Jan 53 (01) 146-152
• Herr HW, Sogani PC.. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 2001; Oct 166 (04) 1296-1299
• Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M.. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000; Mar 163 (03) 761-767
• Dalbagni G, Russo P, Bochner B, Ben-Porat L, Sheinfeld J, Sogani P. et al Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; Jun 24 (18) 2729-2734
• Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA.. Impact of previous bacille Calmette- Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy. Urology 2008; Feb 71 (02) 297-301
• Herr HW, Milan TN, Dalbagni G.. BCG-refractory vs. BCG-relapsing non-muscle- invasive bladder cancer: a prospective cohort outcomes study. Urol Oncol 2015; Mar 33 (03) 108.e1-4
• Bui TT, Schellhammer PF.. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997; May 49 (05) 687-690
• Meyer J, Persad R, Gillatt DA.. Use of bacille Calmette-Guérin in superficial bladder cancer. Postgrad Med J 2002; Aug 78 (922) 449-454
• Herr HW, Donat SM.. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 2001; Jan 165 (01) 62-64
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S. et al Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; Feb 19 (03) 666-675
• Lightfoot AJ, Rosevear HM, O'Donnell MA.. Recognition and treatment of BCG failure in bladder cancer. Sci World J 2011; Mar 11: 602-613
• Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR.. The treated natural history of high-risk superficial bladder cancer: 15-year outcome. J Urol 1997; Jul 158 (01) 62-67
• Sylvester RJ, Van Der Meijden AP, Witjes JA, Kurth K.. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005; Jul 174 (01) 86-91
• Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B. et al Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol 2011; Oct 186 (04) 1261-1268
• Raj GV, Herr H, Serio AM, Donat SM, Bochner BH, Vickers AJ. et al Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007; 177 (04) 1283-1286
• Bianco Junior FJ, Justa D, Grignon DJ, Sakr WA, Pontes JE, Wood Junior DP.. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 2004; Jul/Aug 22 (04) 290-294
• Chang SS, Cookson MS.. Non-muscle-invasive bladder cancer: the role of radical cystectomy. Urology 2005; Nov 66 (%) 917-922
• Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R. et al Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; Feb 21 (04) 690-696
• Stein JP.. Indications for early cystectomy. Urology 2003; Oct 62 (04) 591-595
• Montie JE.. Against bladder sparing: surgery. J Urol 1999; Aug 162 (02) 452-455 discussion:455-7
• Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh QD, Nguyen PL. et al Impact of centralizing care for genitourinary malignancies to high-volume providers: a systematic review. Eur Urol Oncol 2019; 2: 265-273
• Scarberry K, Berger NG, Scarberry KB, Agrawal S, Francis JJ, Yih JM. et al Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival. Urol Oncol 2018; Apr 36 (06) 308.e11-e17
• Santos F, Zakaria AS, Kassouf W, Tanguay S, Aprikian A.. High hospital and surgeon volume and its impact on overall survival after radical cystectomy among patients with bladder cancer in Quebec. World J Urol 2015; Sep 33 (09) 1323-1330
• Kim SP, Shah ND, Karnes RJ, Weight CJ, Frank I, Moriarty JP. et al The implications of hospital acquired adverse events on mortality, length of stay and costs for patients undergoing radical cystectomy for bladder cancer. J Urol 2012; Jun 187 (06) 2011-2017
• Williams SB, Huo J, Chamie K, Hu JC, Giordano SH, Hoffman KE. et al Underutilization of radical cystectomy among patients diagnosed with clinical stage T2 muscle-invasive bladder cancer. Eur Urol Focus 2017; Apr 3 (2–3): 258-264
• Zattoni F, Palumbo V, Giannarini G, Crestani A, Kungulli A, Novara G. et al Perioperative outcomes and early survival in octogenarians who underwent radical cystectomy for bladder cancer. Urol Int 2018; 100 (01) 13-17
• Pang KH, Groves R, Venugopal S, Noon AP, Catto JWF.. Prospective implementation of enhanced recovery after surgery protocols to radical cystectomy. Eur Urol 2018; Mar 73 (03) 363-371
• Chipollini J, Tang DH, Hussein K, Patel SY, Garcia-Getting RE, Pow-Sang JM. et al Does implementing an enhanced recovery after surgery protocol increase hospital charges? Comparisons from a radical cystectomy program at a specialty cancer center. Urology 2017; Jul 105: 108-112
• Hautmann RE, Stein JP.. Neobladder with prostatic capsule and seminal-sparing cystectomy for bladder cancer: a step in the wrong direction. Urol Clin North Am 2005; May 32 (02) 177-185
• Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH.. Adjuvant chemotherapy for muscle- invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials. Oncotarget 2017; 8 (46) 81204-14
• Steven K, Poulsen AL.. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only. J Urol 2007; Oct 178 4 Pt 1 1218-1223
• Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M. et al Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004; Jan 171 (01) 139-144
• Gschwend JE, Heck MM, Lehmann J, Rubben H, Albers P, Wolff JM. et al Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial. Eur Urol 2019; Apr 75 (04) 604-611
• Cody JD, Nabi G, Dublin N, McClinton S, Neal DE, Pickard R. et al Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. Cochrane Database Syst Rev 2012; 2012 (02) CD003306
• Ali AS, Hayes MC, Birch B, Dudderidge T, Somani BK.. Health related quality of life (HRQoL) after cystectomy: comparison between orthotopic neobladder and ileal conduit diversion. Eur J Surg Oncol 2015; Mar 41 (03) 295-299
• Stein R, Hohenfellner M, Pahernik S, Roth S, Thüroff JW, Rübben H.. Urinary diversion-approaches and consequences. Dtsch Arztebl Int 2012; Sep 109 (38) 617-622
• Zhou X, Ji H, Zhang H, Xiong T, Pan J, Chen Z.. Treatment and outcomes of urethral recurrence after orthotopic neobladder replacement in patients with bladder cancer - practice in a single centre. J Int Med Res 2018; Sep 46 (09) 3928-3937
• Hassan JM, Cookson MS, Smith Junior JA, Chang SS.. Urethral recurrence in patients following orthotopic urinary diversion. J Urol 2004; Oct 172 4 Pt 1 1338-1341
• Yamashita S, Hoshi S, Ohyama C, Satoh M, Soma F, Okada Y. et al Urethral recurrence following neobladder in bladder cancer patients. Tohoku J Exp Med 2003; Apr 199 (04) 197-203
• Levinson AK, Johnson DE, Wishnow KI.. Indications for urethrectomy in an era of continent urinary diversion. J Urol 1990; Jul 144 (01) 73-75
• Nahar B, Koru-Sengul T, Miao F, Prakash NS, Venkatramani V, Gauri A. et al Comparison of readmission and short-term mortality rates between different types of urinary diversion in patients undergoing radical cystectomy. World J Urol 2018; 36 (03) 393-399
• Monn MF, Kaimakliotis HZ, Cary KC, Pedrosa JA, Flack CK, Koch MO. et al Short- term morbidity and mortality of Indiana pouch, ileal conduit, and neobladder urinary diversion following radical cystectomy. Urol Oncol 2014; Nov 32 (08) 1151-1157
• Mao SY, Xiong DB, Huang TB, Cai KK, Xu L, Zheng JH. et al Urinary diversion by neobladder reconstruction after radical cystectomy in the elderly: outcomes and survival. Int J Clin Exp Med 2016; 9 (12) 23576-83
• Malavaud B, Vaessen C, Mouzin M, Rischmann P, Sarramon J, Schulman C.. Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score. Eur Urol 2001; Jan 39 (01) 79-84
• Longo N, Imbimbo C, Fusco F, Ficarra V, Mangiapia F, Di Lorenzo G. et al Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy. BJU Int 2016; Oct 118 (04) 521-526
• Deliveliotis C, Papatsoris A, Chrisofos M, Dellis A, Liakouras C, Skolarikos A.. Urinary diversion in high-risk elderly patients: modified cutaneous ureterostomy or ileal conduit?. Urology 2005; Aug 66 (02) 299-304
• Hautmann RE, Volkmer BG, Schumacher MC, Gschwend JE, Studer UE.. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 2006; Aug 24 (03) 305-314
• Fontenot PA, Barnes BD, Parker WP, Wyre H, Lee EK, Holzbeierlein JM.. Postoperative outcomes after radical cystectomy in patients with prior pelvic radiation. Urology 2018; Jun 116: 131-136
• Faba OR, Tyson MD, Artibani W, Bochner BH, Burkhard F, Gilbert SM. et al Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. World J Urol 2019; Jan 37 (01) 85-93
• Holzbeierlein JM, Lopez-Corona E, Bochner BH, Herr HW, Donat SM, Russo P. et al Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; Sep 172 (03) 878-881
• Chang SS, Cookson MS, Baumgartner RG, Wells N, Smith Junior JA.. Analysis of early complications after radical cystectomy: results of a collaborative care pathway. J Urol 2002; 167 (05) 2012-2016
• Fahmy N, Aprikian A, Tanguay S, Mahmud SM, Al-Otaibi M, Jeyaganth S. et al Practice patterns and recurrence after partial cystectomy for bladder cancer. World J Urol 2010; Aug 28 (04) 419-423
• Dandekar NP, Tongaonkar HB, Dalal AV, Kulkarni JN, Kamat MR.. Partial cystectomy for invasive bladder cancer. J Surg Oncol 1995; Sep 60 (01) 24-29
• Herr HW, Scher HI.. Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 1994; 12 (05) 975-980
• Sweeney P, Kursh ED, Resnick MI.. Partial cystectomy. Urol Clin North Am 1992; Nov 19 (04) 701-711
• Knoedler JJ, Boorjian SA, Kim SP, Weight CJ, Thapa P, Tarrell RF. et al Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol 2012; Oct 188 (04) 1115-1119
• Hussain MH, Glass TR, Forman J, Sakr W, Smith DC, Al-Sarraf M. et al Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 2001; Jan 165 (01) 56-60 discussion:60-1
• Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Radiation Therapy Oncology Group. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer 2003; Apr 97 (8 Suppl 1): 2115-2119
• Zietman A, Hunt D, Kaufman D, Uzzo R, Wu C, Buyyounouski MK. et al Preliminary results of RTOG 0233: a phase II randomized trial for muscle-invading bladder cancer treated by transurethral resection and radiotherapy comparing two forms of concurrent induction chemotherapy. Int J Radiat Oncol Biol Phys 2010; Nov 78 (3 Suppl 1): S31-S2
• Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP. et al Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; Dec 32 (34) 3801-3809
• Rödel C, Grabenbauer GG, Kühn R, Papadopoulos T, Dunst J, Meyer M. et al Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; Jul 20 (14) 3061-3071
• Turgeon GA, Souhami L.. Trimodality therapy for bladder preservation in the elderly population with invasive bladder cancer. Front Oncol 2014; Aug 4: 206
• Smith ZL, Christodouleas JP, Keefe SM, Malkowicz SB, Guzzo TJ.. Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy. BJU Int 2013; Jul 112 (01) 13-25
• Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM. et al Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts general hospital experience. Eur Urol 2017; Jun 71 (06) 952-960
• Vashistha V, Wang H, Mazzone A, Liss MA, Svatek RS, Schleicher M. et al Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2017; Apr 97 (05) 1002-1020
• Arcangeli G, Arcangeli S, Strigari L. A. systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC). Crit Rev Oncol Hematol 2015; Apr 94 (01) 105-115
• Weiss C, Sauer R, Rödel C.. Radiochemotherapeutic options for bladder cancer. Aktuelle Urol 2008; Mar 39 (02) 123-129
• Weiss C, Wolze C, Engehausen DG, Ott OJ, Krause FS, Schrott KM. et al Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy?. J Clin Oncol 2006; May 24 (15) 2318-2324
• Wo JY, Shipley WU, Dahl DM, Coen JJ, Heney NM, Kaufman DS. et al The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?. BJU Int 2009; Jul 104 (02) 179-183
• Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ. et al Radical trimodality therapy for patients with locally advanced bladder cancer: the British Columbia Cancer Agency experience. Urol Oncol 2015; 33 (02) 66.e13-9
• Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C. et al Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation. Int J Radiat Oncol Biol Phys 2014; Mar 88 (03) 603-610
• Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM. et al Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol 2014; Jul 66 (01) 120-137
• Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG. et al Long-term outcomes among patients who achieve complete or near-complete responses after the induction phase of bladder-preserving combined-modality therapy for muscle-invasive bladder cancer: a pooled analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 2016; Jan 94 (01) 67-74
• Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK. et al Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; Jul 60 (01) 62-67 discussion:67-8
• Lewis GD, Haque W, Verma V, Butler EB, Teh BS.. The role of adjuvant radiation therapy in locally advanced bladder cancer. Bladder Cancer 2018; Apr 4 (02) 205-213
• Zaghloul MS, Christodouleas JP, Smith A, Abdallah A, William H, Khaled HM. et al Adjuvant sandwich chemotherapy plus radiotherapy vs adjuvant chemotherapy alone for locally advanced bladder cancer after radical cystectomy: a randomized phase 2 trial. JAMA Surg 2018; Jan 153 (01) e174591
• Zaghloul M, Christodouleas JP, Hwang WT, Smith A, Abdalla A, William H. et al Randomized phase III trial of adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy: Urothelial carcinoma subgroup analysis. J Clin Oncol 2019; 37 (7 Suppl 1): S351
• Bryant CM, Dang LH, Stechmiller BK, Gilbert SM, Morris CG, Zlotecki RA.. Treatment of small cell carcinoma of the bladder with chemotherapy and radiation after transurethral resection of a bladder tumor. Am J Clin Oncol 2016; Feb 39 (01) 69-75
• Premo C, Apolo AB, Agarwal PK, Citrin DE.. Trimodality therapy in bladder cancer: who, what, and when?. Urol Clin North Am 2015; May 42 (02) 169-180